AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00613054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zactima, Gleevec, Hydroxyurea
Description: Pts will start treatment on day 1 of cycle 1 w Zactima, imatinib mesylate \& hydroxyurea. All 3 agents administered in continuous daily, oral manner. Imatinib mesylate dose 400 mg/day for pts not on EIAEDs \& 1000 mg/day for pts on EIAEDs based on previous studies demonstrating that pts on EIAEDs require significantly higher doses of imatinib mesylate \& that such doses are safe \& well tolerated. Dose of hydroxyurea 500 mg twice day. Dose level of Zactima will be increased in successive cohorts of pts as described below.~Cohorts of 3-6 pts will accrue at each dose level until MTD is defined. Each cohort will consist of a mini of 3 newly enrolled pts. Intra-patient dose escalation is not permitted. Cohorts may be expanded at any dose level for further elaboration of safety \& pharmacokinetic parameters as required.~Treatment cycle is defined as daily administration of Zactima + imatinib mesylate \& hydroxyurea for 28 days for purpose of scheduling evaluations.
Study NCT01252810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE-145
Description: GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.
Study NCT01252810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GE-145
Description: GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.
Study NCT00636467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No name
Description: Injection of Nanocis® or Nanocoll® on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)
Study NCT02885194 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Laser-Evoked potential
Description: Laser-Evoked potential can document lesions of spinothalamic tract and lateral brainstem and of thalamo-cortical projections conducting nociceptive signals. The rapid heating of skin by infrared laser pulses stimulate small fibers sensory pathways. The main cortical laser evoked potential is a complex of components N2-P2. Evaluation of the registered potentials includes shape, latency and amplitude.
Study NCT02304848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS (Deep Brain Stimulation)
Description: Applying low frequency and high frequency deep brain stimulation to subthalamic nucleus.
Study NCT02347488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haider ETT Tube Holder and Bite Guard
Description: Surgery patients will have endotracheal tubes secured with a novel combined endotracheal tube holder and bite guard change in ETT tip position caused by traction up to 15N was measured prior to surgery.
Study NCT02347488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tape
Description: Surgery patients will have endotracheal tubes secured with adhesive tape, as the current clinical procedure; change in ETT tip position caused by traction up to 15N measured prior to re-securing the ETT with the Haider device.
Study NCT00686296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Taliderm™
Description: taliderm™ dressing application once
Study NCT00686296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Taliderm™
Description: Taliderm™ dressing application up to three applications
Study NCT00686296 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard wet to dry dressing with gauze
Description: wet to dry dressing standard of care
Study NCT01167751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MNC
Description: Implantation of BM derived MNC
Study NCT01167751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AC 133
Description: Implantation of BM derived AC133
Study NCT01167751 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Injection of cell carrier
Study NCT00792454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: Subjects will undergo renal rehabilitation in the form of guided exercises 2 times per week for 3 months. Subjects will be encouraged to walk for 1 hour on their own a third day of the week.Subjects will receive recommendations for cardiovascular, weight training and stretching exercises.~Cardiovascular and strength capabilities of all subjects will be evaluated at the initial session in order to prescribe the appropriate exercise regimen. An exercise physiologist will conduct these evaluations using the Perceived Level of Exertion Subjects will also receive education and practice in mindful meditation and a heart healthy diet.~Subjects will be encouraged to continue exercises, meditation, and healthy eating habits after the 3-month in-center program. Subjects will receive follow-up phone calls at 3-month intervals to encourage ongoing exercise, meditation, and healthy diet.
Study NCT02448693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WLE
Description: Evaluation of the polypectomy scar with High Definition White Light Endoscopy (WLE)
Study NCT02448693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBI
Description: Evaluation of the polypectomy scar with Narrow Band Imaging (NBI, Evis Exera III, Olympus).
Study NCT01162239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid. Participants in the Extended Relapse Prevention plus varenicline will receive varenicline for up to 40 additional weeks.
Study NCT01162239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Initial Individual counseling
Description: Five 90 minute individual counseling sessions to occur during the first 12 weeks of initial treatment.
Study NCT01162239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check-ins with medical staff
Description: Monthly brief (10-15 minutes) meetings with medical staff.
Study NCT01162239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Individual Counseling - Health Model
Description: Monthly counseling sessions across a nine month period with content based on a health education model. Each session is 30-45 minutes in duration.
Study NCT01162239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Individual Counseling - Relapse Prevention Model
Description: Eleven individual counseling sessions across a nine month period with content based on a relapse prevention model. Each session is 30-45 minutes in duration.
Study NCT02204384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFD Meal: High fiber from food
Description: High amount of fiber from diet food sources (HFD; total fiber 9.7g; soluble fiber 5.4g)
Study NCT02204384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HFS Meal: High fiber from supplement
Description: High amount of soluble fiber from guar gum supplement (HFS; total fiber 9.1g; soluble fiber 5.4g) - sachet 5 g Fiber Mais, Nestlé Brasil, São Paulo, BR
Study NCT02204384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UF Meal: usual amount of fiber
Description: Usual amount of fiber (UF; total fiber 2.4g; soluble fiber 0.8g)
Study NCT02568475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of Go to the Hospital or Stay Here?
Description: Residents and families randomly assigned to the intervention group (one half of the residents and one half of the families enrolled) are given the new Decision Aid to review with an RA trained for this purpose by the investigators. The Decision Aid provides information on risks and benefits of acute care transfer and information on advance care planning, resident and families' right to be involved in the decision. Resident or family member is also asked to re-read it and think about it over the subsequent 14 days.
Study NCT01298583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ankle tracking training
Description: one group will use the ankle for tracking, the other group will use the ankle for simple movement
Study NCT00417040 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: internet-based intervention
Description: Use the STAR database system
Study NCT00417040 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: assessment of therapy complications
Description: Use the STAR database system
Study NCT00417040 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04136184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inotersen
Description: Inotersen by subcutaneous injection
Study NCT04136184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplontersen
Description: Eplontersen by subcutaneous injection
Study NCT04136184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplontersen
Description: Eplontersen by subcutaneous injection
Study NCT02780674 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI7734
Description: Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
Study NCT02780674 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
Study NCT04454437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously
Study NCT02575404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR-MD-02
Description: Patients will receive five doses of GR-MD-02 intravenously over 85 Days.
Study NCT02575404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.
Study NCT02659579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Reader Organisation's Shared Reading Programme
Description: In The Reader Organisation's Shared Reading Programme, parents and children will attend weekly shared book reading sessions for 8 weeks which focus predominately on how to read interactively with children.
Study NCT02659579 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared Reading control
Description: Parents and children will attend a weekly shared reading group at a library for 8 weeks
Study NCT02129205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650808
Description: Dose Escalation Phase \[Part 1\] - PF-06650808 will be administered at doses starting at 0.2 mg/kg. Increases in dose will continue until MTD is determined.
Study NCT02129205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650808
Description: Dose Expansion Phase \[Part 2\] - Patients will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
Study NCT04304781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSP/QRH dimer
Description: Peptide 919288G, Lot No. 17081402, Molecular Weight 3577.0, ≥95% purity. Stored at \<20°C. Dark green, lyophilized powder in single-use amber vials.
Study NCT04319302 — intervention group
Intervention type: PROCEDURE
Intervention: Isolated Vascularized Gastric Tube (IVGT) graft
Description: A conduit was created by tubularising a vascularized segment of the greater curve of the antrum of the stomach and this was used between the remaining common hepatic duct and the duodenum.
Study NCT03599895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D printing model
Description: Combine the 3D printing technique with imaging examination ,making the 3D model of da Vinci robot assisted radical gastrectomy
Study NCT03599895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non 3D printing model
Description: da Vinci robot assisted radical gastrectomy
Study NCT01553877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pushti packet
Description: A food composed of roasted rice, roasted lentil, molasses and soybean oil
Study NCT01553877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice based Ready to Use Complementary Food Supplements
Description: A rice based diet.
Study NCT01553877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chick-pea based Ready to Use Complementary Food Supplements
Description: A chick-pea based diet.
Study NCT01530412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Patients undergo pulmonary rehabilitation for two hours twice a week for seven weeks. The first hour comprises of an individualized exercise programme and the second hour consists of an educational component. Patients are also required to undergo inspiratory muscle training five days a week for thirty minutes and exercise for an additional three days a week for thirty minutes.
Study NCT04275297 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Treatment
Description: The psychosocial intervention will consist of 8 weekly 50-minute individual visits with the assigned therapist.
Study NCT04275297 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: The Attention Control will reflect a similar visit pattern and duration as intervention sessions.
Study NCT01816412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD02-LDCB Paclitaxel coated balloon catheter
Study NCT01816412 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Uncoated Balloon Angioplasty Catheter
Study NCT02987179 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Collect anthropomorphic, WatchPAT, Crit-line Monitor measurements as well as sleep questionnaires and video records
Study NCT00956267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles
Study NCT00956267 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian diathermy (LOD)
Description: Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
Study NCT02449681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-4000 (Tarloxotinib)
Study NCT03019471 — intervention group
Intervention type: GENETIC
Intervention: Isolation of tumor DNA
Study NCT01081457 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep brain stimulation
Description: Comparison ON vs OFF
Study NCT01081457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: Comparison ON vs OFF
Study NCT02795533 — intervention group
Intervention type: BEHAVIORAL
Intervention: Clinical follow-up
Description: All included patients will have a clinical follow-up consisting of:~1. A medical examination~2. Quality of life questionnaires~3. Neuropsychological test~All instruments have been translated into Norwegian and validated and tested in clinical practice.
Study NCT03760341 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adenoidectomy - cold method
Description: a surgery for adenoid removal or reduction under general anesthesia using surgical curretes
Study NCT03760341 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adenoidectomy - hot method
Description: a surgery for adenoid removal or reduction under general anesthesia using suction diathermy
Study NCT04260412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medium cut-off (MCO) dialysis membrane
Description: Medium cut-off dialysis (MCO) membrane is a dialysis membrane with a higher molecular weight retention onset and similar cut-off as standard high-flux dialysis membranes. It is capable of providing increased clearance of medium sized uremic toxins and some plasma proteins (cytokines, inflammatory mediators).
Study NCT04260412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary fiber mixture (Plantago Psyllium 69% and Inulin 30%)
Description: Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.
Study NCT04260412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber mixture (Plantago Psyllium 69% and Inulin 30%)
Description: Dietary fiber (Psyllium 69% and Inulin 30% mixture) added to the meals in the dose of 5g BID for 4 weeks in the second phase of the study.
Study NCT04260412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium propionate
Description: Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.
Study NCT04260412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium propionate
Description: Sodium propionate (a short-chain fatty acid) added to the meals in the dose of 500 mg BID in the second phase in the study.
Study NCT04870359 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-emptive increase of immunosuppressive treatments
Description: 1. Increase prednisolone to 0.4-0.5 mg/kg/day; taper by 5 mg every 2 weeks to reach 15mg/day; then further reduce by 2.5 mg every 2 week and aim to reach 5-7.5 mg/day after 12 weeks.~2. Adjustment of the 2nd agent would be as follows:~   1. For patients who receive AZA \<75mg/day; increase the dose of AZA to 75 mg/day.~  2. For patients who receive MMF \<1g/day, increase the dose of MMF to 1g/day.
Study NCT04870359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone and/or AZA/MMF
Description: Prednisolone and/or AZA/MMF
Study NCT00831181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 50mg/m2 weekly dosing during RT (Day 1)
Study NCT00831181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Folinic Acid (Leucovorin): 400 mg/m2; 2-hour IV infusion simultaneously with oxaliplatin
Study NCT00831181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mesorectal excision
Description: mesorectal excision
Study NCT03418714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salvinorin A
Description: Salvinorin A, blinded doses
Study NCT00783068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride]
Description: Subjects will receive GTS-21 or placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of GTS-21 or placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0)
Study NCT00783068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
Study NCT05215132 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: MRI
Description: 1.5T or 3T MRI scanner (Siemens Medical Systems)
Study NCT05215132 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gadavist 2Ml Solution for Injection
Description: Arm 1 and Arm 3 subjects will undergo this intervention (Gadavist 2Ml solution)
Study NCT00523718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riluzole
Description: 50 mg PO bid, 12 weeks
Study NCT00523718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, 1 capsule PO bid, 12 weeks
Study NCT01277770 — intervention group
Intervention type: DRUG
Intervention: Steroid-Free Maintenance Immunosuppression
Description: 10 year follow-up of steroid-free maintenance immunosuppression
Study NCT01277770 — intervention group
Intervention type: OTHER
Intervention: Infection After Kidney Transplantation
Description: A cross-sectional study of infection after kidney transplantation (with emphasis on infection in steroid-free recipients).
Study NCT01277770 — intervention group
Intervention type: DRUG
Intervention: Evaluation of the DGF nomogram in Thymoglobulin
Description: An evaluation of the DGF nomogram in Thymoglobulin treated recipients at the University of Minnesota
Study NCT04156503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palm olein vs Lard
Description: A 5-hour postprandial feeding intervention with 2-weeks washout in between. Blood samples will be collected at hour 0 (baseline) before test meal, and hour 3, 4 and 5 after consumption of test meal.
Study NCT02017041 — intervention group
Intervention type: DEVICE
Intervention: Medsignals
Description: MedSignals (www.medsignals.com) is a cellular communicating medication management device designed to improve adherence. It will be used to track when medication is removed from the device at dosing times and deliver audible and visual alerts at dosing times and to relay adherence data securely to patient files. Participants will use this device throughout the 5-week trial. It is a Class I device.
Study NCT02017041 — intervention group
Intervention type: DEVICE
Intervention: smartphone app
Description: The smartphone app being evaluated in this study is designed to support effective medication management of opioid substitution patients taking buprenorphine/naloxone.